Patent intelligence · IL
IL 240179
Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject
Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophil…
Patent details — IL 240179
- Jurisdiction
- IL
- Status
- granted
- Grant date
- Dec 31, 2018
- Expiration
- Dec 26, 2038
- Applicant
- BIOWA INC [US]
- CPC classes
- A61K/39395, A61P/1100, A61P/1106, A61P/2900
Quick answer
IL 240179 (Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject) is held by BIOWA INC [US]. Status: granted. Granted Dec 31, 2018. Expires Dec 26, 2038 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOWA INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/39395, A61P/1100, A61P/1106, A61P/2900, A61P/3700, A61P/3702
More from BIOWA INC [US]
Related pharmaceutical patents in our USPTO index.
-
ZA 201308176
THERAPEUTIC TREATMENT
granted -
SI 2158199
PIPERIDINE COMPOUNDS AND USES THEREOF
granted -
US 2010280048
Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
granted -
DO P2009000148
DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES
granted -
EP 2086964
BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN
granted -
EP 2079730
MGLUR5-MODULATOREN
granted -
EP 2064340
VERFAHREN ZUR BEWERTUNG VON PATIENTEN BEI DER BEHANDLUNG MIT AUF RET-REZEPTOR-TYROSINKINASE ABZIELENDEN ARZNEISTOFFEN
granted
Frequently asked questions
What is US patent 240179?
IL 240179 (Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject) is held by BIOWA INC [US]. Status: granted. Granted Dec 31, 2018. Expires Dec 26, 2038 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns IL 240179?
BIOWA INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does IL 240179 expire?
Our index shows an expiration date of Dec 26, 2038 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.